4.7 Article

N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 Mpro Dimer

Journal

JOURNAL OF MOLECULAR BIOLOGY
Volume 433, Issue 13, Pages -

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2021.167003

Keywords

3CL protease; coronavirus; proteolytic inhibitor; COVID-19; antivirals; enzyme mechanism; SARS; GC373

Funding

  1. CIHR
  2. NSERC [SOF-549297-2019]
  3. Li Ka Shing Institute of Virology
  4. GSK Chair in Virology
  5. Alberta Innovates Graduate Scholarship
  6. Alberta Graduate Excellence Scholarship
  7. CIHR Vanier Scholarship
  8. U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-76SF00515]
  9. DOE Office of Biological and Environmental Research
  10. National Institutes of Health, National Institute of General Medical Sciences [P41GM103393]

Ask authors/readers for more resources

The main protease of SARS-CoV-2 is a high priority drug target, and GC376 has been shown to effectively inhibit it. GC376 also demonstrates reversible binding and broad specificity, making it suitable for clinical trials. The stability and thermodynamic parameters of the protease were studied, revealing insights into the physical chemical properties of viral enzymes.
The main protease (M-pro, also known as 3CL protease) of SARS-CoV-2 is a high priority drug target in the development of antivirals to combat COVID-19 infections. A feline coronavirus antiviral drug, GC376, has been shown to be effective in inhibiting the SARS-CoV-2 main protease and live virus growth. As this drug moves into clinical trials, further characterization of GC376 with the main protease of coronaviruses is required to gain insight into the drug's properties, such as reversibility and broad specificity. Reversibility is an important factor for therapeutic proteolytic inhibitors to prevent toxicity due to off-target effects. Here we demonstrate that GC376 has nanomolar K-i values with the M-pro from both SARS-CoV-2 and SARS-CoV strains. Restoring enzymatic activity after inhibition by GC376 demonstrates reversible binding with both proteases. In addition, the stability and thermodynamic parameters of both proteases were studied to shed light on physical chemical properties of these viral enzymes, revealing higher stability for SARS-CoV-2 M-pro. The comparison of a new X-ray crystal structure of M-pro from SARS-CoV complexed with GC376 reveals similar molecular mechanism of inhibition compared to SARS-CoV-2 M-pro, and gives insight into the broad specificity properties of this drug. In both structures, we observe domain swapping of the N-termini in the dimer of the M-pro, which facilitates coordination of the drug's P1 position. These results validate that GC376 is a drug with an off-rate suitable for clinical trials. (C) 2021 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available